Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-04-25 @ 12:40 PM
Study NCT ID:
NCT04864834
Status:
COMPLETED
Last Update Posted:
2024-03-26
First Post:
2021-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Sponsor:
Sandoz
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CSOK583A12301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None